China Soy Imports at Record as US Spat Spurs More Brazil Flows
China's soybean imports climbed to an all-time high last month as the world's biggest buyer scooped up large volumes mainly from Brazil amid concerns that its trade war with the US could boost global prices.
Soybean purchases by the Asian nation more than doubled from a month earlier to 13.92 million tons in May, China's customs data showed. Imports rose 73% in April.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
United States Diabetes Devices and Therapeutics Market Investment Opportunities Report 2025
The U.S. diabetes market is projected to grow at a CAGR of 7.2% from 2025-2029, reaching $39.33 billion. Key trends include real-time monitoring adoption, digital health integration, advanced delivery systems, and supportive regulatory frameworks. The report provides a data-centric analysis of market dynamics and opportunities. U.S. Diabetes Devices and Therapeutics Market Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "United States Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to diabetes market in United States is expected to grow by 8.4% on annual basis to reach US$27.62 billion in diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 9.1%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.2% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 25.47 billion to approximately USD 39.33 billion. The U.S. diabetes devices and therapeutics market is undergoing significant shifts with real-time monitoring, digital integration, advanced delivery systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures while emphasizing data integration and precise patient management. The U.S. diabetes devices and therapeutics market is characterized by a mix of established players and new entrants. Strategic partnerships, acquisitions, and the integration of digital health solutions are reshaping competitive dynamics. In the coming years, market consolidation and targeted innovation are expected to further define the competitive environment, influencing product offerings and patient management Adoption of Real-Time Glucose Monitoring U.S. healthcare providers increasingly use continuous glucose monitoring (CGM) systems to track patient glucose levels in real-time. Large healthcare networks have adopted CGM systems to support outpatient diabetes management. Recent publications indicate improvements in insurance reimbursement policies and favorable regulatory reviews. Enhanced clinical data on the reliability of CGM systems reinforces their use in routine diabetes care. Adoption is expected to increase, driven by wider coverage and enhanced device integration with electronic health records. The trend will likely intensify as more clinical studies validate the benefits of real-time monitoring in reducing long-term complications. Integrate Digital Health Solutions into Diabetes Management U.S. providers are integrating device data with telehealth platforms and remote patient monitoring systems for diabetes management. Examples include healthcare systems deploying centralized digital dashboards to monitor patient metrics remotely. Recent industry reports highlight a shift in healthcare delivery models that suggests a push toward digital transformation in chronic disease management. Insurance models increasingly support telehealth consultations and remote monitoring, aligning with broader medtech trends. The integration of digital platforms is expected to grow, promoting data-driven decision-making and enhancing care coordination. This trend will likely intensify, leading to a more efficient tracking of treatment adherence and patient outcomes. Advance Therapeutic Delivery Systems The market is witnessing the emergence of devices that support precise therapeutic delivery, such as smart insulin pens. U.S. manufacturers are introducing systems for accurate dosing and treatment adherence monitoring. Technological advancements in device miniaturization and data analytics are facilitating the development of these delivery systems. Recent healthcare publications note a rising focus on improving patient safety and treatment precision in diabetes care. Market penetration of smart delivery systems is expected to grow, influenced by evolving clinical practice guidelines and supportive reimbursement frameworks. This trend will intensify as precision therapy becomes a central focus in diabetes management. Regulatory and Reimbursement Frameworks Recent changes in FDA and CMS policies support integrating digital tools in diabetes care. Updated guidelines and expanded reimbursement criteria for digital health applications evidence these regulatory adjustments. Broader healthcare policy initiatives for cost containment and improved patient outcomes drive these regulatory changes. Publications from the past year highlight a response to the increased demand for remote monitoring and digital therapeutics. Regulatory support is expected to maintain momentum, enabling continued investment in digital health and advanced therapeutics. The framework will further intensify market adoption of compliant and data-integrated devices. Current Market ConditionsThe market comprises established manufacturers and emerging firms. A diverse portfolio of devices and therapeutics is present, ranging from established CGM systems to new smart delivery devices. Assess Key Competitors and Emerging Entrants Major companies, such as large medical device manufacturers and specialized diabetes care firms, hold significant market share. Established firms maintain comprehensive product portfolios covering both devices and therapeutics. New market entrants focus on integrating digital health solutions with diabetes management systems. These entrants bring targeted innovations, complementing the existing product mix in the U.S. market. Examine Strategic Partnerships and Corporate Activities Recent publications document acquisitions of smaller digital health companies by established device manufacturers. Strategic partnerships have been initiated between healthcare systems and technology firms to expand remote monitoring capabilities. The market shows signs of consolidation driven by competitive pressures and regulatory incentives. Collaborative efforts are aimed at enhancing integrated care delivery and data analytics capabilities. Future Competitive Dynamics Continued consolidation and strategic alliances are expected as established players seek to enhance their technological offerings. New entrants with digital health expertise will likely drive niche innovations, altering competitive positioning. Over the next 2-4 years, the competitive landscape will likely evolve with intensified competition and targeted market consolidation. Companies will increasingly leverage partnerships to improve patient data integration and therapeutic outcomes. Key Attributes: Report Attribute Details No. of Pages 50 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $29.83 Billion Forecasted Market Value (USD) by 2029 $39.33 Billion Compound Annual Growth Rate 7.2% Regions Covered United States ScopeDiabetes Devices and Therapeutics Market Share by Category Diagnosis and Monitoring Devices Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Blood Glucose Monitoring Devices Insulin Delivery Devices Diabetes Management and Mobile Applications Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Insulin Pumps Insulin Pens Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs GLP-1 Receptor Agonists Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs Combination Insulin Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration Subcutaneous Intravenous Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes Type 1 Diabetes Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User Hospitals Diabetes Clinics Homecare For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Diabetes Devices and Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Bloomberg
an hour ago
- Bloomberg
Here's Why China Is a Key Player in the Israel-Iran Conflict
China has condemned Israel's recent attack on Iran, while offering to play a positive role in facilitating dialogue between the two countries. China's economic ties to the region add to its geopolitical heft - and it's the latest example of Beijing's growing role as a global power-broker and diplomatic force.
Bloomberg
an hour ago
- Bloomberg
Nidec CEO Stresses Compliance in Shift From Fixation on Growth
Nidec Corp. founder Shigenobu Nagamori said the Japanese maker of precision motors is prioritizing compliance, stepping away from a half-century-long focus on profit and growth. The acquisitive company is now teaching employees about the importance of contributing to society, even if that means additional costs, Nagamori said at the annual shareholders' meeting Friday in Kyoto. Nidec earlier this week delayed its submission of its securities report over errors in country-of-origin declarations and unpaid import tariffs at a subsidiary in Italy.
